Identification of tumor rejection antigens and the immunologic landscape of medulloblastoma.

ABSTRACT:

Background

The current standard of care treatments for medulloblastoma are insufficient as these do not take tumor heterogeneity into account. Newer, safer, patient-specific treatment approaches are required to treat high-risk medulloblastoma patients who are not cured by the standard therapies. Immunotherapy is a promising treatment modality that could be key to improving survival and avoiding morbidity. For an effective immune response, appropriate tumor antigens must be targeted. While medulloblastoma patients with subgroup-specific genetic substitutions have been previously reported, the immunogenicity of these genetic alterations remains unknown. The aim of this study is to identify potential tumor rejection antigens for the development of antigen-directed cellular therapies f

SUBMITTER: Yang C 

PROVIDER: S-EPMC11331754 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature